|Written by Rob Goldman|
Once again, we have pored over some great data and have re-introduced what may be the best indicator for the stock market. It has been right 87% of the time since 1967! Depending upon what happens in the next 2 weeks, we might even see a huge return this year. Why? Read on…
Best Stock Market Indicator
Some of you may recall that we completed a very detailed study on a crazy, but incredibly accurate stock market indicator. Based upon recent events, we have some key insights as to direction and magnitude.
What are we talking about?
I know it sounds crazy but football is the key to success of the stock market in 2013. And the odds are promising for some good gains this year…maybe. Regardless, at Goldman Small Cap Research, we have pored over 46 years of data and have come to the conclusion that the Super Bowl Indicator may be the most accurate investing predictor we have come across.
To put it in perspective, this indicator has been right 87% of the time since 1967!
The Super Bowl Indicator is a prediction tool that purports to accurately forecast whether or not the market will rise or fall, based upon the winner of the current year’s Super Bowl. If the winner of the Super Bowl traces its roots to the old National Football League (pre-NFL-AFL merger), it is a sign that the market will rise. If the winner traces its roots to the AFL, it is a sign that the market will likely decline. There have been 46 Super Bowls since 1967 and teams that trace their roots to the old NFL have won 33 times. The market has risen in 28 of those 33 years. On the other hand, teams that trace their roots to the old AFL have won 12 times, with the market rising only 6 out of those 12 times. (We exclude the Tampa Bay Super Bowl win as it joined the league post the merger.)
But, it is so much more than just being right 28 out of 33 times. It is the magnitude of the wins and losses, and I hate to admit, which NFL-related club wins.
Super Bowl Indicator
As illustrated above, when NFL-based teams have won, and the market has risen (which has happened 28 out of 33 times), the S&P 500 Index has jumped an average of 13.2%. Conversely, in the six declines measured by the AFL-led winning teams, the Index dropped an average of over 15%.
Armed with these historical performance statistics, it is clear we should always root for traditional NFL teams to win the Super Bowl. With that said, how are things looking for his year?
For starters, both the San Francisco 49ers and (my) Baltimore Ravens trace their roots to the old NFL, so right off the bat we should be in good shape. Of course, the S&P 500 is already up over 4% and we are barely 3 weeks into the new year, so that might appear obvious to some investors. If we drill down further, we see some very interesting data. While the S&P 500 has risen 13.2% on average for these NFL-related teams, not all teams are created equal.
The San Francisco 49ers have won the Super Bowl 5 times from 1982 – 1995. Four out of those years the S&P 500 returned a monster average gain of 25.6%. In the year the market declined, the index dropped by 6.6%. Thus, the average return for all 49er Super Bowl victories is 19.2%.
Conversely, the Baltimore Ravens, which traces its roots through the old Cleveland Browns, won the Super Bowl in its only appearance in 2001. The index dropped by 13%, but of course there were extenuating circumstances due to the 9/11 tragedy.
The bottom line? In the aggregate, we should be in good shape, especially if you throw out the “fluke” 2001 year. If you prefer not to do that, than perhaps you should root against my Ravens and cheer for a 49er victory. After all 4 out of 5 big gains isn’t a bad thing. February 3rd, here we come…
Small Drug Stock Making $
Last week, we highlighted a stock we felt is a good buy at current levels, given the expected huge EPS growth in 2013.
Lannett Company, Inc. (NYSE – LCI - $5.79) is a small pharmaceutical company that traces its roots to 1942. The Company’s current oral and topical drug portfolio includes generics related to a wide variety of ailments such as glaucoma, Parkinson’s disease, migraines, antibiotic, anesthetic, endometriosis, obesity, congestive heart failure, pain management, etc.
Investors should expect that progress in the introduction of new offerings in the fast-growing pain management segment and enhancing its R&D and production capabilities in this treatment category should be a boost to the Company’s already strong growth over the next year or so.
The stock has been on fire over the past 2 months, climbing from the $4.00 range to the present levels. Current EPS estimates for the June 2013 year are $0.18 per share and EPS is expected to jump to $0.31 in its next fiscal year. It is possible that these estimates could be light given that LCI already reported 1Q13fiscal EPS of $0.10 on a 25% rise in revenue from 1Q12.
The chart looks great and the stock is a hair under its year high. The only overhang we see is the recently revised shelf registration filed a month ago which would enable the Company and shareholders to sell as much as $64M in stock and debt securities. While management stated it has no plans to utilize this shelf right now, it clearly will down the road, in our view, which could increase the float and/or cause modest dilution. Still, with an annual revenue-run rate in excess of $130M, nice profitability, a huge product portfolio, and an aged company and leadership, we would not be surprised to see LCI be snatched up this year.
If management continues to hit on all cylinders, LCI could be a $7.00 in a year’s time.
Until next week….
Analyst: Robert Goldman
Rob Goldman founded Goldman Small Cap Research (GSCR) in 2009. Rob has over 20 years of investment and research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, he was a senior member of Piper Jaffray's Technology team. Prior to joining Piper, Rob led Josephthal & Co.'s Emerging Growth Research Group. Rob has also served as Chief Investment Officer of two boutique investment management firms, where he managed Small Cap Growth and Balanced portfolios and The Blue and White Fund. As an investment manager, Rob's model portfolio was once ranked the 4th best small cap growth performer in the U.S. by Money Manager Review. In addition to his work at GSCR, Rob is the editor of Penny Stock Junction (www.pennystockjunction.com.)
I, Robert Goldman, hereby certify that the view expressed in this newsletter accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research publication.
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap and mid cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This report or newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report or newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.